Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 44, 2010, Pages 19084-19089

  Everaerts, Wouter ^a,b,c   Zhen, Xiaoguang ^d   Ghosh, Debapriya ^a,c   Vriens, Joris ^a,c   Gevaert, Thomas ^b,e   Gilbert, James P ^d   Hayward, Neil J ^d   McNamara, Colleen R ^d,f   Xue, Fenqin ^a,c   Moran, Magdalene M ^d   Strassmaier, Timothy ^d   Uykal, Eda ^d   Owsianik, Grzegorz ^a,c   Vennekens, Rudi ^a,c   De Ridder, Dirk ^b,c   Nilius, Bernd ^a,c   Fanger, Christopher M ^d   Voets, Thomas ^a,c  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^b SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Hydra Biosciences   (United States)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f TUFTS UNIVERSITY   (United States)

Author keywords

Transient receptor potential channels; Urothelium

Indexed keywords

CYCLOPHOSPHAMIDE; HC 067047; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 4; VANILLOID RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLADDER CAPACITY; BLADDER DYSFUNCTION; BLADDER FUNCTION; CONFERENCE PAPER; CONTROLLED STUDY; CYSTITIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TARGETING; HUMAN; HUMAN CELL; MICTURITION; MOUSE; NONHUMAN; POLLAKISURIA; PRIORITY JOURNAL; RAT; UROTHELIUM;

MUS; RATTUS;

EID: 78650479042     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1005333107     Document Type: Article

References (41)

1. Andersson KE, Arner A (2004) Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 84:935-986.
2. Ouslander JG (2004) Management of overactive bladder. N Engl J Med 350:786-799.
3. Fowler CJ, Griffiths D, de Groat WC (2008) The neural control of micturition. Nat Rev Neurosci 9:453-466.
4. Abrams P, et al. (2002) The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 187:116-126.
5. Kannan H, Radican L, Turpin RS, Bolge SC (2009) Burden of illness associated with lower urinary tract symptoms including overactive bladder/urinary incontinence. Urology 74:34-38.
6. Irwin DE, et al. (2009) Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: Impact of overactive bladder. Eur Urol 56:14-20.
7. Chapple CR, et al. (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543-562.
8. Andersson KE, et al. (2009) Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 19:380-394.
9. Hegde SS (2006) Muscarinic receptors in the bladder: From basic research to therapeutics. Br J Pharmacol 147(Suppl 2):S80-S87.
10. Nilius B, Owsianik G, Voets T, Peters JA (2007) Transient receptor potential cation channels in disease. Physiol Rev 87:165-217.
11. Everaerts W, Nilius B, Owsianik G (2010) The vallinoid transient receptor potential channel TRPV4: From structure to disease. Prog Biophys Mol Biol 103:2-17.
12. Yamada T, et al. (2009) Differential localizations of the transient receptor potential channels TRPV4 and TRPV1 in the mouse urinary bladder. J Histochem Cytochem 57: 277-287.
13. Thorneloe KS, et al. (2008) N-((1S)-1-[4-((2S)-2-[(2,4-dichlorophenyl) sulfonyl]amino-3-hydroxypropanoyl)-1-piperazinyl]carbonyl-3-methylbutyl) -1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I. J Pharmacol Exp Ther 326:432-442.
14. 2+ influx and ATP release in primary urothelial cell cultures. J Biol Chem 284: 21257-21264.
15. Gevaert T, et al. (2007) Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest 117:3453-3462.
16. Everaerts W, et al. (2010) Functional characterization of transient receptor potential channels in mouse urothelial cells. Am J Physiol Renal Physiol 298:F692-F701.
17. Geppetti P, Nassini R, Materazzi S, Benemei S (2008) The concept of neurogenic inflammation. BJU Int 101(Suppl 3):2-6.
18. Cox PJ (1979) Cyclophosphamide cystitis.Identification of acrolein as the causative agent. Biochem Pharmacol 28:2045-2049.
19. D'hoedt D, et al. (2008) Stimulus-specific modulation of the cation channel TRPV4 by PACSIN 3. J Biol Chem 283:6272-6280.
20. Cuajungco MP, et al. (2006) PACSINs bind to the TRPV4 cation channel. PACSIN 3 modulates the subcellular localization of TRPV4. J Biol Chem 281:18753-18762.
21. Saban MR, Nguyen NB, Hammond TG, Saban R (2002) Gene expression profiling of mouse bladder inflammatory responses to LPS, substance P, and antigen-stimulation. Am J Pathol 160:2095-2110.
22. -/- mice. Proc Natl Acad Sci USA 100:13698-13703.
23. Lee H, Iida T, Mizuno A, Suzuki M, Caterina MJ (2005) Altered thermal selection behavior in mice lacking transient receptor potential vanilloid 4. J Neurosci 25: 1304-1310.
24. Charrua A, et al. (2009) GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol 181: 379-386.
25. Birder L, et al. (2007) Activation of urothelial transient receptor potential vanilloid 4 by 4α-phorbol 12, 13-didecanoate contributes to altered bladder reflexes in the rat. J Pharmacol Exp Ther 323:227-235.
26. Vriens J, et al. (2004) Cell swelling, heat, and chemical agonists use distinct pathways for the activation of the cation channel TRPV4. Proc Natl Acad Sci USA 101:396-401.
27. Cockayne DA, et al. (2000) Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407:1011-1015.
28. Ito K, Iwami A, Katsura H, Ikeda M (2008) Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. Naunyn Schmiedebergs Arch Pharmacol 377:483-490.
29. Cenac N, Altier C, Chapman K, Liedtke W, Zamponi G, Vergnolle N (2008) Transient receptor potential vanilloid-4 has a major role in visceral hypersensitivity symptoms. Gastroenterology 135:937-946.
30. Vergnolle N, et al. (2010) A role for transient receptor potential vanilloid 4 in tonicityinduced neurogenic inflammation. Br J Pharmacol 159:1161-1173.
31. Masuyama R, et al. (2008) TRPV4-mediated calcium influx regulates terminal differentiation of osteoclasts. Cell Metab 8:257-265.
32. Mizuno A, Matsumoto N, Imai M, Suzuki M (2003) Impaired osmotic sensation in mice lacking TRPV4. Am J Physiol Cell Physiol 285:C96-C101. (Pubitemid 36736341)
33. Suzuki M, Mizuno A, Kodaira K, Imai M (2003) Impaired pressure sensation in mice lacking TRPV4. J Biol Chem 278:22664-22668. (Pubitemid 36830325)
34. Tabuchi K, Suzuki M, Mizuno A, Hara A (2005) Hearing impairment in TRPV4 knockout mice. Neurosci Lett 382:304-308.
35. Willette RN, et al. (2008) Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2. J Pharmacol Exp Ther 326:443-452.
36. Rock MJ, et al. (2008) Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia. Nat Genet 40:999-1003.
37. Krakow D, et al. (2009) Mutations in the gene encoding the calcium-permeable ion channel TRPV4 produce spondylometaphyseal dysplasia, Kozlowski type and metatropic dysplasia. Am J Hum Genet 84:307-315.
38. Auer-Grumbach M, et al. (2010) Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet 42: 160-164.
39. Deng HX, et al. (2010) Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4. Nat Genet 42:165-169.
40. Landoure G, et al. (2010) Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C. Nat Genet 42:170-174.
41. Nilius B, Owsianik G (2010) Channelopathies converge on TRPV4. Nat Genet 42: 98-100.